<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361294</url>
  </required_header>
  <id_info>
    <org_study_id>TechnischeUM 1</org_study_id>
    <nct_id>NCT02361294</nct_id>
  </id_info>
  <brief_title>Immature Plateletes in the Etiopathology of Deep Venous Thrombosis</brief_title>
  <acronym>iPLATELET</acronym>
  <official_title>Prospective Study to Generate Hypotheses About the Role of Platelets and Immature Platelets in the Pathogenesis of Idiopathic Venous Thromboses and Pulmonary Embolisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the role of platelets and immature platelets in the&#xD;
      ethiopathology of deep venous thrombosis and pulmonary embolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">April 7, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Significantly increased proportion of immature platelets in patients with deep venous thrombosis and/or pulmonary embolism compared to the control.</measure>
    <time_frame>at time of diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significantly higher values of platelet function in patients with deep venous thrombosis and/or pulmonary embolism compared to the control.</measure>
    <time_frame>at time of diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A persistently increased proportion of immature platelets in patients with deep venous thrombosis and/or pulmonary embolism compared to the controls three months after diagnosis.</measure>
    <time_frame>3 months after diagnosis</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Immature Platelets</condition>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <description>Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      thrombophilia screening&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        all-comers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The&#xD;
             thrombembolism is idiopathic or caused by immobilisation.&#xD;
&#xD;
          -  Control: Patients that present with a suspicion of deep venous thrombosis which is&#xD;
             excluded by duplex sonography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  therapy with glycoprotein IIb/IIIa-antagonists within the last 10 days&#xD;
&#xD;
          -  therapy with antiplatelet drugs (ASA, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamol)&#xD;
&#xD;
          -  preexisting anticoagulation&#xD;
&#xD;
          -  number of platelets &lt; 100.000/µl&#xD;
&#xD;
          -  anemia (hematocrit &lt; 35%, Hb &lt; 10 g/dl)&#xD;
&#xD;
          -  age &gt; 80 y or &lt; 18 y&#xD;
&#xD;
          -  renal insufficiency GFR &lt; 30 ml/min&#xD;
&#xD;
          -  hepatic impairment with an increased risk for bleeding or coagulopathy, or liver&#xD;
             cirrhosis (≥ Child Pugh B)&#xD;
&#xD;
          -  intracranial or intracerebral bleeding within the last six months&#xD;
&#xD;
          -  intraspinal or intracerebral vascular anomalies&#xD;
&#xD;
          -  clinically relevant acute bleedings&#xD;
&#xD;
          -  malign disease&#xD;
&#xD;
          -  infections within the last 7 d&#xD;
&#xD;
          -  hematological, rheumatologic and autoimmune diseases&#xD;
&#xD;
          -  operations within the last six months&#xD;
&#xD;
          -  transfusion of rec celll concentrates within the last six months&#xD;
&#xD;
          -  transfusion of fresh frozen plasma or platelet concentrates within the last month&#xD;
&#xD;
          -  preexisting medication with CYP 3A4 inhibitors and inductors, p-glycoprotein&#xD;
             inhibitors (Azol-Antimycotis, HIV protease-inhibitors)&#xD;
&#xD;
          -  hypersensitivity/contraindications for Rivaroxaban&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  thrombophilia&#xD;
&#xD;
          -  thrombocytopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tareq Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

